| ONE-CUSTOMER |
ONE-CUSTOMER |
90%
|
For the three months ended September 30, 2023, approximately 77 % of all receivables related to kidneyintelX.dkd testing services revenue related to one customer |
| TWO-CUSTOMERS |
TWO-CUSTOMERS |
90%
|
For the three months ended September 30, 2024, approximately 74 % of all receivables related to kidneyintelX.dkd and KidneyIntelX technology testing services revenue related to two customers |
| OTHER-PARTY-PAYORS |
OTHER-PARTY-PAYORS |
80%
|
approximately 23 % of receivables were due from other party payors |
| OTHER-THIRD-PARTY-PAYORS |
OTHER-THIRD-PARTY-PAYORS |
80%
|
the remaining 26 % of receivables were due from other third-party payors |
| ABT |
Abbott Laboratories |
72%
|
taining or establishing new laboratory space to support these commercialization and development efforts, or if our potential future ex-United States laboratory operations are harmed or are rendered i… |
| ABT |
Abbott Laboratories |
72%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from RNLXY graph: taining or establishing new laboratory space to support these commercialization and development efforts, or if our po… |
| BIO |
Bio-Rad Laboratories, Inc. |
72%
|
Reciprocal relationship from BIO graph: Reciprocal relationship from RNLXY graph: taining or establishing new laboratory space to support these commercialization and development efforts, or if our po… |
| BIO |
Bio-Rad Laboratories, Inc. |
72%
|
taining or establishing new laboratory space to support these commercialization and development efforts, or if our potential future ex-United States laboratory operations are harmed or are rendered i… |
| ELV |
Elevance Health, Inc. |
72%
|
Reciprocal relationship from ELV graph: Reciprocal relationship from RNLXY graph: nt (the "Joslin Option Agreement") with Joslin for patent filings on certain additional novel biomarkers in kidney di… |
| ELV |
Elevance Health, Inc. |
72%
|
nt (the "Joslin Option Agreement") with Joslin for patent filings on certain additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX platform. We believe that… |
| ABBOTT-LABORATORIES-BIO-RAD-LABORATORIES-INC |
ABBOTT-LABORATORIES-BIO-RAD-LABORATORIES-INC |
62%
|
taining or establishing new laboratory space to support these commercialization and development efforts, or if our potential future ex-United States laboratory operations are harmed or are rendered i… |
| AMERICA-HOLDINGS |
AMERICA-HOLDINGS |
62%
|
taining or establishing new laboratory space to support these commercialization and development efforts, or if our potential future ex-United States laboratory operations are harmed or are rendered i… |
| CVI-INVESTMENTS-INC |
CVI-INVESTMENTS-INC |
62%
|
15, 2024, and the adoption of this standard is not anticipated to have a significant impact on the Company’s consolidated financial statements other than adding new disclosures, which the Company is … |
| HEIGHTS-CAPITAL-IRELAND-LLC |
HEIGHTS-CAPITAL-IRELAND-LLC |
62%
|
mmercializing licensed products or processes, if we fail to maintain certain required insurance policies, and if we fail to pay patent expenses related to the licensed patents. Recent Developments • … |
| KANTARO-BIOSCIENCES-LLC |
KANTARO-BIOSCIENCES-LLC |
62%
|
. F- 9 Fair value of financial instruments At June 30, 2024 and 2023 , the Company’s financial instruments included accounts receivable, prepaid expenses and other current assets, accounts payable, a… |
| KIDNEYINTELX-MESO-SCALE-DIAGNOSTICS-LLC |
KIDNEYINTELX-MESO-SCALE-DIAGNOSTICS-LLC |
62%
|
ively validated biomarkers for CKD; 12 • partnerships with healthcare systems; • validated prognostic performance; • technical performance and innovation to deliver products that provide clinically a… |
| MESO-SCALE-DIAGNOSTICS-LLC |
MESO-SCALE-DIAGNOSTICS-LLC |
62%
|
ssociated materials and may not be able to find replacements or immediately transition to alternative suppliers. We have sourced and will continue to source components of our technology, including in… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
of, all potentially available relevant information. Forward-looking statements include statements about: • the ability to execute our plans for commercialization of KidneyIntelX; • the timing and pla… |
| QUEST-DIAGNOSTICS-INC |
QUEST-DIAGNOSTICS-INC |
62%
|
taining or establishing new laboratory space to support these commercialization and development efforts, or if our potential future ex-United States laboratory operations are harmed or are rendered i… |
| RENALYTIX-AI-INC |
RENALYTIX-AI-INC |
62%
|
ognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Foreign currency The Company’s consolidated financial statements are presented in U.S. dollars, the… |
| RENALYTIX-AI-LIMITED |
RENALYTIX-AI-LIMITED |
62%
|
ognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Foreign currency The Company’s consolidated financial statements are presented in U.S. dollars, the… |
| THERMOFISHER-SCIENTIFIC-INC-DANAHER-CORPORATION- |
THERMOFISHER-SCIENTIFIC-INC-DANAHER-CORPORATION- |
62%
|
taining or establishing new laboratory space to support these commercialization and development efforts, or if our potential future ex-United States laboratory operations are harmed or are rendered i… |
